[go: up one dir, main page]

MX2019011795A - Composicion dirigida al gen s1pr4 para prevenir o tratar la esteatohepatitis no alcoholica. - Google Patents

Composicion dirigida al gen s1pr4 para prevenir o tratar la esteatohepatitis no alcoholica.

Info

Publication number
MX2019011795A
MX2019011795A MX2019011795A MX2019011795A MX2019011795A MX 2019011795 A MX2019011795 A MX 2019011795A MX 2019011795 A MX2019011795 A MX 2019011795A MX 2019011795 A MX2019011795 A MX 2019011795A MX 2019011795 A MX2019011795 A MX 2019011795A
Authority
MX
Mexico
Prior art keywords
gene
s1pr4
prevent
alcoholic steatohepatitis
composition
Prior art date
Application number
MX2019011795A
Other languages
English (en)
Other versions
MX388653B (es
Inventor
Hee Koh Eun
Up Lee Ki
Hee Kim Sang
Duk Kim Dae
Original Assignee
Univ Ulsan Found Ind Coop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ulsan Found Ind Coop filed Critical Univ Ulsan Found Ind Coop
Publication of MX2019011795A publication Critical patent/MX2019011795A/es
Publication of MX388653B publication Critical patent/MX388653B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una composición dirigida al gen S1PR4 para prevenir o tratar la esteatohepatitis no alcohólica, y más particularmente, con una composición farmacéutica y una composición saludable de alimento funcional, ambas comprendiendo un compuesto esfingolípido el cual sirve como inhibidor funcional contra el gen S1PR4, mostrando profilaxis y terapia para la esteatohepatitis no alcohólica. Se espera que el compuesto esfingolípido de la presente invención se aplique como un material principal efectivo para la prevención o tratamiento de la esteatohepatitis no alcohólica (NASH, por sus siglas en inglés) debido a que tiene el efecto de reducir la infiltración de células inflamatorias en tejidos hepáticos y suprimir la fibrosis, y disminuye un nivel de lesión hepática (ALT), la inflamación en tejidos hepáticos, y la expresión de un gen relacionado con la fibrosis.
MX2019011795A 2017-03-29 2018-03-29 Composicion dirigida al gen s1pr4 para prevenir o tratar la esteatohepatitis no alcoholica. MX388653B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170040139A KR102292989B1 (ko) 2017-03-29 2017-03-29 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
PCT/KR2018/003711 WO2018182329A1 (ko) 2017-03-29 2018-03-29 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
MX2019011795A true MX2019011795A (es) 2020-01-27
MX388653B MX388653B (es) 2025-03-20

Family

ID=63677916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011795A MX388653B (es) 2017-03-29 2018-03-29 Composicion dirigida al gen s1pr4 para prevenir o tratar la esteatohepatitis no alcoholica.

Country Status (11)

Country Link
US (1) US11571435B2 (es)
EP (1) EP3603636A4 (es)
JP (1) JP6890805B2 (es)
KR (1) KR102292989B1 (es)
CN (1) CN110475554B (es)
AU (2) AU2018246796B2 (es)
BR (1) BR112019020262A2 (es)
CA (1) CA3058124C (es)
MX (1) MX388653B (es)
SA (1) SA519410204B1 (es)
WO (1) WO2018182329A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
KR102105880B1 (ko) * 2018-10-26 2020-04-29 서울대학교병원 비알코올 지방간 질환의 조직학적 중증도 진단 또는 예후 측정에 관한 정보 제공 방법
KR102540720B1 (ko) * 2020-02-18 2023-06-08 재단법인 아산사회복지재단 천식 또는 기관지염 예방 또는 치료용 약학적 조성물
JP7799262B2 (ja) * 2020-09-22 2026-01-15 慶北大学校 産学連携財団 グレリン受容体作用剤としてのトリアゾール化合物の用途
WO2023043024A1 (en) * 2021-09-15 2023-03-23 Nextgen Bioscience Pharmaceutical composition for preventing or treating interstitial fibrosis and tubular atrophy as a functional antagonist for s1pr1 and s1pr4
WO2023042996A1 (en) * 2021-09-15 2023-03-23 Nextgen Bioscience Pharmaceutical composition for preventing or treating focal segmental glomerulosclerosis acting as a functional antagonist for s1pr1 and s1pr4
KR102533409B1 (ko) * 2021-11-04 2023-05-26 주식회사 넥스트젠바이오사이언스 2-아미노-2-(2-(1-데실-1h-1,2,3-트라이아졸-4-일)에틸)프로판-1,3-다이올의 신규염 및 이를 포함하는 약학적 조성물
JP7465041B1 (ja) 2022-03-23 2024-04-10 ネクストジェン バイオサイエンス カンパニー リミテッド Ｓ１ｐｒ１とｓ１ｐｒ４に対する機能的拮抗剤として作用する炎症性腸疾患の予防または治療用薬学的組成物
KR20230161357A (ko) * 2022-05-18 2023-11-27 주식회사 넥스트젠바이오사이언스 S1pr1과　s1pr4에 대한 기능적 저해제로 작용하는 방사선 유발 폐 섬유증의 예방 또는 치료용 약학적 조성물
KR102541577B1 (ko) * 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물
MX2023011556A (es) * 2022-10-21 2024-07-19 Nextgen Bioscience Co Ltd Composición farmacéutica para prevenir o tratar la alopecia areata actuando como un antagonista funcional de s1pr1 y s1pr4.
CN118252881B (zh) * 2022-12-26 2025-07-25 成都中医药大学 一种用于治疗非酒精性脂肪性肝病、肝纤维化和/或肝硬化的药物组合物及制备方法和用途
WO2024237668A1 (ko) * 2023-05-15 2024-11-21 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4를 표적으로 하는 조절제 투여방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392167T3 (es) 2003-04-30 2012-12-05 Novartis Ag Derivados aminopropanol como moduladores del receptor esfingosina-1-fosfato
AU2007323540A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
WO2010068775A2 (en) * 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
SG11201507459YA (en) * 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
US9738613B2 (en) 2015-05-18 2017-08-22 National Central University Substituted 1,2,3-triazoles as antitumor agents
KR20170025909A (ko) * 2015-08-31 2017-03-08 가천대학교 산학협력단 스핑고신 1-인산 또는 Sphk2의 발현을 상승시키는 물질을 포함하는 대사 기능 장애의 예방 또는 치료용 약학 조성물
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US11571435B2 (en) 2023-02-07
CN110475554B (zh) 2022-12-30
CA3058124A1 (en) 2018-10-04
JP2020512369A (ja) 2020-04-23
EP3603636A4 (en) 2020-12-30
JP6890805B2 (ja) 2021-06-18
AU2021202271A1 (en) 2021-05-06
SA519410204B1 (ar) 2022-09-01
WO2018182329A1 (ko) 2018-10-04
KR20180110499A (ko) 2018-10-10
AU2018246796B2 (en) 2021-04-01
EP3603636A1 (en) 2020-02-05
AU2018246796A1 (en) 2019-10-17
US20210100820A1 (en) 2021-04-08
MX388653B (es) 2025-03-20
CN110475554A (zh) 2019-11-19
CA3058124C (en) 2022-07-05
BR112019020262A2 (pt) 2020-04-22
KR102292989B1 (ko) 2021-08-26

Similar Documents

Publication Publication Date Title
MX2019011795A (es) Composicion dirigida al gen s1pr4 para prevenir o tratar la esteatohepatitis no alcoholica.
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
PH12017501384A1 (en) Pharmaceutical compositions for combination therapy
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2022002489A (es) Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MX2017009532A (es) Uso de acidos grasos de cadena corta en prevencion de cancer.
SG178873A1 (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
GEP201706663B (en) Novel composition for nonalcoholic fatty liver disease (nafld
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
BR112018071031A2 (pt) combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
CL2021000018A1 (es) Oligonucleótidos para modular la expresión de rtel1
MX2021014410A (es) Composiciones y métodos para tratar la enfermedad metabólica.
WO2021041561A3 (en) Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
AU2016245434A8 (en) Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
PE20242220A1 (es) Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer
BR112022001602A2 (pt) Composição e método para prevenir, aliviar ou tratar lesão hepática
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.